BioLineRx : Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER ...
Source: marketscreener.com
Stay updated with breaking news from Gloria Bioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER ...
Ligand's (LGND) Captisol technology is a key driver for its topline. The company plans to spin off another potential technology platform, OmniAb, into a separate company.